Ligand Pharmaceuticals, Inc. (LGND)
286.85
-0.09
(-0.03%)
USD |
NASDAQ |
Nov 20, 16:00
286.93
+0.08
(+0.03%)
After-Hours: 20:00
Ligand Pharmaceuticals Research and Development Expense (TTM) : 23.09M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 23.09M |
| June 30, 2026 | 41.35M |
| March 31, 2026 | 33.24M |
| December 31, 2025 | 81.18M |
| September 30, 2025 | 82.10M |
| June 30, 2025 | 66.75M |
| March 31, 2025 | 65.54M |
| December 31, 2024 | 21.42M |
| September 30, 2024 | 22.51M |
| June 30, 2024 | 22.44M |
| March 31, 2024 | 24.37M |
| December 31, 2023 | 25.44M |
| September 30, 2023 | 29.16M |
| June 30, 2023 | 32.77M |
| March 31, 2023 | 34.13M |
| December 31, 2022 | 36.28M |
| September 30, 2022 | 35.27M |
| June 30, 2022 | 42.99M |
| March 31, 2022 | 50.62M |
| December 31, 2021 | 58.78M |
| September 30, 2021 | 72.34M |
| June 30, 2021 | 68.25M |
| March 31, 2021 | 64.71M |
| December 31, 2020 | 56.29M |
| September 30, 2020 | 37.45M |
| Date | Value |
|---|---|
| June 30, 2020 | 38.34M |
| March 31, 2020 | 37.82M |
| December 31, 2019 | 40.18M |
| September 30, 2019 | 46.08M |
| June 30, 2019 | 37.82M |
| March 31, 2019 | 31.75M |
| December 31, 2018 | 27.86M |
| September 30, 2018 | 27.66M |
| June 30, 2018 | 26.93M |
| March 31, 2018 | 25.62M |
| December 31, 2017 | 26.89M |
| September 30, 2017 | 24.66M |
| June 30, 2017 | 25.80M |
| March 31, 2017 | 25.89M |
| December 31, 2016 | 21.22M |
| September 30, 2016 | 17.69M |
| June 30, 2016 | 13.73M |
| March 31, 2016 | 12.83M |
| December 31, 2015 | 12.79M |
| September 30, 2015 | 13.12M |
| June 30, 2015 | 14.19M |
| March 31, 2015 | 12.87M |
| December 31, 2014 | 12.04M |
| September 30, 2014 | 11.22M |
| June 30, 2014 | 10.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 16.02B |
| Eli Lilly & Co. | 15.38B |
| Bristol Myers Squibb Co. | 9.479B |
| Xeris Biopharma Holdings, Inc. | 38.38M |
| LENZ Therapeutics, Inc. | 0.00 |